GlobalData on MSN11d
Boehringer Ingelheim reports positive results from trial of HER2 lung cancer drug
The trial met its primary endpoint, showing a meaningful objective response rate and a tolerable safety profile for ...
Boehringer Ingelheim faces second hung jury in Chicago Zantac trial
The latest trial over claims that the discontinued heartburn drug Zantac causes cancer ended with a hung jury on Wednesday, ...
ENDPOINTS NEWS5d
Boehringer plans NDA fil­ing for pul­monary fi­bro­sis drug fol­low­ing Phase 3 da­ta
A Phase 3 trial investigating Boehringer Ingelheim’s nerandomilast in idiopathic pulmonary fibrosis hit its primary endpoint, ...
BioWorld2d
Boehringer Ingelheim divulges new NOX4 inhibitors
Boehringer Ingelheim Pharma GmbH & Co. KG has synthesized NADPH oxidase 4 (NOX4) inhibitors reported to be useful for the treatment of atherosclerosis, cancer, pulmonary hypertension, inflammatory ...